Beta Bionics (BBNX) Competitors $10.48 +0.02 (+0.19%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock BBNX vs. LMAT, ENOV, NVCR, CNMD, WRBY, CDRE, KMTS, TNDM, FNA, and LQDAShould you be buying Beta Bionics stock or one of its competitors? The main competitors of Beta Bionics include LeMaitre Vascular (LMAT), Enovis (ENOV), NovoCure (NVCR), CONMED (CNMD), Warby Parker (WRBY), Cadre (CDRE), Kestra Medical Technologies (KMTS), Tandem Diabetes Care (TNDM), Paragon 28 (FNA), and Liquidia (LQDA). These companies are all part of the "medical equipment" industry. Beta Bionics vs. LeMaitre Vascular Enovis NovoCure CONMED Warby Parker Cadre Kestra Medical Technologies Tandem Diabetes Care Paragon 28 Liquidia Beta Bionics (NASDAQ:BBNX) and LeMaitre Vascular (NASDAQ:LMAT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, community ranking, analyst recommendations, institutional ownership, media sentiment, profitability and earnings. Do insiders and institutionals have more ownership in BBNX or LMAT? 84.6% of LeMaitre Vascular shares are held by institutional investors. 10.8% of LeMaitre Vascular shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts rate BBNX or LMAT? Beta Bionics currently has a consensus price target of $24.83, suggesting a potential upside of 136.96%. LeMaitre Vascular has a consensus price target of $95.25, suggesting a potential upside of 12.55%. Given Beta Bionics' stronger consensus rating and higher probable upside, analysts clearly believe Beta Bionics is more favorable than LeMaitre Vascular.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Beta Bionics 0 Sell rating(s) 3 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.78LeMaitre Vascular 0 Sell rating(s) 4 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.67 Does the media favor BBNX or LMAT? In the previous week, LeMaitre Vascular had 8 more articles in the media than Beta Bionics. MarketBeat recorded 10 mentions for LeMaitre Vascular and 2 mentions for Beta Bionics. LeMaitre Vascular's average media sentiment score of 1.48 beat Beta Bionics' score of 0.96 indicating that LeMaitre Vascular is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beta Bionics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LeMaitre Vascular 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher earnings and valuation, BBNX or LMAT? LeMaitre Vascular has higher revenue and earnings than Beta Bionics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBeta Bionics$65.12M6.98N/AN/AN/ALeMaitre Vascular$219.86M8.68$30.10M$1.9443.62 Is BBNX or LMAT more profitable? LeMaitre Vascular has a net margin of 19.40% compared to Beta Bionics' net margin of 0.00%. LeMaitre Vascular's return on equity of 13.15% beat Beta Bionics' return on equity.Company Net Margins Return on Equity Return on Assets Beta BionicsN/A N/A N/A LeMaitre Vascular 19.40%13.15%11.47% Does the MarketBeat Community favor BBNX or LMAT? LeMaitre Vascular received 509 more outperform votes than Beta Bionics when rated by MarketBeat users. Likewise, 70.45% of users gave LeMaitre Vascular an outperform vote while only 66.67% of users gave Beta Bionics an outperform vote. CompanyUnderperformOutperformBeta BionicsOutperform Votes666.67% Underperform Votes333.33% LeMaitre VascularOutperform Votes51570.45% Underperform Votes21629.55% SummaryLeMaitre Vascular beats Beta Bionics on 11 of the 14 factors compared between the two stocks. Remove Ads Get Beta Bionics News Delivered to You Automatically Sign up to receive the latest news and ratings for BBNX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BBNX vs. The Competition Export to ExcelMetricBeta BionicsSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$454.30M$4.07B$5.33B$7.57BDividend YieldN/A39.50%5.11%4.32%P/E RatioN/A27.6321.7317.81Price / Sales6.9850.20379.2094.61Price / CashN/A51.0838.1534.64Price / BookN/A5.826.464.00Net IncomeN/A$67.09M$3.20B$247.23M7 Day Performance7.93%5.64%6.54%7.26%1 Month Performance-28.56%-3.20%-8.55%-6.26%1 Year PerformanceN/A14.87%10.33%-0.18% Beta Bionics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BBNXBeta BionicsN/A$10.48+0.2%$24.83+137.0%N/A$454.30M$65.12M0.00294LMATLeMaitre Vascular3.2609 of 5 stars$81.36-3.0%$95.25+17.1%+29.6%$1.84B$219.86M44.46490News CoveragePositive NewsENOVEnovis2.2051 of 5 stars$32.00-6.5%$58.50+82.8%-44.9%$1.82B$2.11B-14.616,800Gap DownNVCRNovoCure3.3286 of 5 stars$16.08-5.1%$34.50+114.6%+22.0%$1.77B$605.22M-11.491,320News CoverageCNMDCONMED4.706 of 5 stars$52.34-7.8%$77.20+47.5%-31.7%$1.62B$1.31B12.344,100News CoveragePositive NewsWRBYWarby Parker3.3279 of 5 stars$15.19-8.1%$23.29+53.3%+12.9%$1.57B$771.32M-56.243,030Analyst ForecastNews CoveragePositive NewsGap DownCDRECadre3.4082 of 5 stars$30.09-1.4%$37.00+23.0%-7.0%$1.22B$567.56M36.252,240Gap DownKMTSKestra Medical TechnologiesN/A$24.20+1.5%$27.67+14.3%N/A$1.20B$45.82M0.00300Earnings ReportQuiet Period ExpirationNews CoverageTNDMTandem Diabetes Care4.2061 of 5 stars$17.04-3.2%$43.88+157.5%-49.2%$1.13B$940.20M-8.832,600News CoveragePositive NewsFNAParagon 281.3385 of 5 stars$13.01+0.1%$14.20+9.2%+26.8%$1.09B$256.18M-17.57343,000Short Interest ↓News CoverageHigh Trading VolumeLQDALiquidia2.2428 of 5 stars$12.39-3.0%$26.63+114.9%-0.9%$1.06B$14.00M-7.6050Positive News Remove Ads Related Companies and Tools Related Companies LeMaitre Vascular Competitors Enovis Competitors NovoCure Competitors CONMED Competitors Warby Parker Competitors Cadre Competitors Kestra Medical Technologies Competitors Tandem Diabetes Care Competitors Paragon 28 Competitors Liquidia Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BBNX) was last updated on 4/15/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Beta Bionics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Beta Bionics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BBNX Stock Free BBNX Stock Alerts